


PINTAD

The Pharma Imaging Network for Therapeutics and Diagnostics

Meeting Minutes

Topic	QIBA Survey Results – Phantoms 
Date	26 February 2021
Speaker(s)	Timothy J. Hall

Topic/Slide	Discussion								
DXA	There may not be a role for QIBA in the DXA space.								
Live Poll Results	<p>Poll question: Only half of PINTaD respondents report phantom are important in their work. Are imaging endpoints commonly used in work involving phantoms?</p> <div style="border: 1px solid #ccc; padding: 10px; margin: 10px 0;"> <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="padding: 5px;">All imaging endpoints are involving phantoms in my work</td> <td style="text-align: right; padding: 5px;">9% (2)</td> </tr> <tr> <td style="padding: 5px;">Most of imaging endpoints are involving phantoms in my work</td> <td style="text-align: right; padding: 5px;">36% (8)</td> </tr> <tr> <td style="padding: 5px;">Most of imaging endpoints are NOT involving phantoms in my work</td> <td style="text-align: right; padding: 5px;">40% (9)</td> </tr> <tr> <td style="padding: 5px;">All imaging endpoints are NOT involving phantoms in my work</td> <td style="text-align: right; padding: 5px;">13% (3)</td> </tr> </table> <p style="margin-top: 10px;">22 responses</p> </div>	All imaging endpoints are involving phantoms in my work	9% (2)	Most of imaging endpoints are involving phantoms in my work	36% (8)	Most of imaging endpoints are NOT involving phantoms in my work	40% (9)	All imaging endpoints are NOT involving phantoms in my work	13% (3)
All imaging endpoints are involving phantoms in my work	9% (2)								
Most of imaging endpoints are involving phantoms in my work	36% (8)								
Most of imaging endpoints are NOT involving phantoms in my work	40% (9)								
All imaging endpoints are NOT involving phantoms in my work	13% (3)								
Phantom use in PINTaD	<p>Comment from the chat: Rarely use phantoms even with quantitative imaging due to operational issues usually</p> <p><i>Live discussion:</i></p> <ul style="list-style-type: none"> What constitutes an imaging biomarker? PINTaD considers imaging a biomarker, and we would love to have them be quantitative The reality in clinical trials is that most of the imaging criteria are semi-quantitative. It is complex, and not always feasible/practical to implement everything that goes along with phantom imaging 								

PINTAD

The Pharma Imaging Network for Therapeutics and Diagnostics

Topic/Slide	Discussion
	<ul style="list-style-type: none">• To what extent can we find a middle ground where the QIBA protocols are more manageable?• Can the increased use of radiomics and AI possibly help to simplify the protocols - to make it more feasible/practical?• There are some applications of quantitative measures that have a lot of known value and variance. Examples:<ul style="list-style-type: none">○ Liver elasticity○ Liver Fat Fraction
Radiomics and AI	<p>Radiomics/AI is a field of interest for PINTaD members with regards to quantification. Need for understanding which confidence in output.</p> <p>FDA had a talk on AI and machine learning: How well do machine learning algorithms work?</p> <ul style="list-style-type: none">• Very well on known data• Not as well when new data is introduced <p>QIBA has created an AI/Radiomics multiparametric TF. QIBA will continue updating profiles with new information and retire profiles as they become outdated.</p>